Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Core Insights - Propanc Biopharma, Inc. is focused on developing treatments for recurring and metastatic cancer, with a recent fiscal year-end update following the filing of its annual 10-K report [1][2] - The company completed an initial public offering and uplisting to Nasdaq on August 14, 2025, which is expected to support future operational and research activities [2] - Propanc aims to create a digital asset treasury of $100 million or greater over the next twelve months, joining over 200 public companies that hold digital assets [2] Financial Performance - Total assets increased significantly from over $72,000 to $19.6 million, primarily due to prepaid service contracts related to various operational activities [6] - Stockholders' equity rose to $13.9 million from a deficit of $3.8 million, indicating a strong improvement in the company's financial position [6] Product Development - The company is developing a novel approach to prevent recurrence and metastasis of solid tumors using pancreatic proenzymes that target cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers [3][4] - The CEO highlighted the focus on advancing the lead therapeutic candidate and building the intellectual property portfolio, with various development milestones anticipated by the end of 2025 and throughout 2026 [2]